Dose distribution in four illustrative cases.

<p>A: medulloblastoma; B: right-sided nephroblastoma; C: median neuroblastoma; D: Hodgkin lymphoma. Left panel: conformal radiotherapy; right panel: helical tomotherapy. PTV contours (white). 95% isodoses (red); 90% isodose (yellow); 50% isodose (green); 5 Gy isodose (blue).</p

Dose to Target volumes.

<p>Dose to Target volumes.</p

Dose to the whole pancreas and to the pancreatic tail in all cases and by tumor location

<p>Dose to the whole pancreas and to the pancreatic tail in all cases and by tumor location</p

Dose to OARs and normal tissue.

<p>Dose to OARs and normal tissue.</p

For each item of QLQ C30 questionnaire, we compare mean score before and 2 months after radiotherapy.

<p>For functional scales (Fig 2a), a high score is related to better QoL and for symptoms scores (Fig 2b), high score is related to high symptoms and worth QoL. Statistically significant variations.</p

Individual changes in global QoL.

<p>Questions 29 and 30 in EORTC QLQ C30 questionnaires enable to calculated a score (from 0 to 100) for global QoL. Variations of this score before and 2 months after radiotherapy are reported here for each patient. There is an important decrease of QoL (≥ 20 points) for 13 patients and a moderate decrease in QoL (10 to 20 points) in 17 patients.</p

Variation of quality of life and symptoms parameters N = 100.

<p>Variation of quality of life and symptoms parameters N = 100.</p

Patient characteristic N = 100.

<p>Patient characteristic N = 100.</p

Predictive factors for moderate changes in quality of life.

<p>Predictive factors for moderate changes in quality of life.</p